Authors
Ines Zugasti, Marina Cornejo, Sandra Castaño-Diez, Juan Jose Rodriguez-Sevilla, Albert Cortes-Bullich, Jordi Esteve, Marina Diaz-Beya
Published in
Experimental hematology & oncology. Volume 15. Issue 1. Oct 16, 2026. Epub Oct 16, 2026.
Abstract
High-risk myelodysplastic syndromes (HR-MDS) are associated with poor survival despite standard therapy with hypomethylating agents (HMAs). Although the VERONA trial did not meet its primary endpoint, a granular interpretation of these results alongside real-life data may help identify patient subsets that could potentially benefit. At the 2025 American Society of Hematology (ASH) Meeting and at the 2026 European Hematology Association Congress (EHA), several studies reported updated data on venetoclax-based combinations in HR-MDS across clinical and biological subgroups. The randomized phase III VERONA study evaluated venetoclax plus azacitidine (VEN/HMA) versus azacitidine alone in the frontline setting, while additional phase I/II and real-life studies explored oral hypomethylating backbones, therapy-related disease, and molecularly defined subsets. Collectively, these data suggest that venetoclax enhances response rates in HR-MDS, although survival benefits remain heterogeneous, with a potential benefit observed when used as a bridge to transplantation. Given the lack of randomized data in transplant-eligible patients, this Correspondence provides a narrative, non-systematic review of the available evidence based mostly on abstracts and not peer reviewed publications. Additionally, we summarize the most clinically relevant findings and discuss their implications for future treatment strategies.
PMID:
42888461
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0